AstraZeneca’s Calquence recommended for approval in EU for treatment of MCL
Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...
Pharmabiz2 天
EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to ...
EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...
PharmiWeb3 天
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and ...
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...